Serotonin syndrome
Reading File
Finding Sources
Searching PubMed
"serotonin syndrome"[MeSH Terms]
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I have excellent, comprehensive content. Now I'll compose the full answer.
Serotonin Syndrome
Serotonin syndrome is a potentially life-threatening toxidrome caused by excess serotonergic activity at central and peripheral receptors. It arises most often from drug interactions rather than single-drug overdose, and is characterized by the classic triad of cognitive changes, autonomic instability, and neuromuscular abnormalities.
Pathophysiology
Excessive stimulation of postsynaptic serotonin receptors - primarily 5-HT1A and 5-HT2A - is responsible for the syndrome. This can result from:
- Increased serotonin synthesis: L-tryptophan supplementation
- Decreased serotonin breakdown: MAO inhibitors
- Increased serotonin release: amphetamines, cocaine, MDMA
- Decreased serotonin reuptake: SSRIs, SNRIs, TCAs, tramadol, meperidine, dextromethorphan
- Direct receptor agonism: triptans, buspirone, LSD
ROSEN's Emergency Medicine, p. 2925
Causative Drugs
High Serotonergic Potency
| Agent | Class |
|---|---|
| MAOIs (phenelzine, tranylcypromine, linezolid) | MAO inhibition |
| Meperidine, tramadol | Opioid analgesics |
| Dextromethorphan | Antitussive |
| Lithium | Mood stabilizer |
| Sumatriptan/triptans | Serotonin agonists |
| L-tryptophan, 5-HTP | Precursors |
Moderate Potency
| Agent | Class |
|---|---|
| SSRIs (fluoxetine, sertraline, paroxetine, citalopram) | Reuptake inhibition |
| SNRIs (venlafaxine, duloxetine) | Reuptake inhibition |
| TCAs (amitriptyline, clomipramine) | Reuptake inhibition |
| Fentanyl, amphetamines, cocaine | Various |
| St. John's wort | Herbal supplement |
| LSD, mescaline | Drugs of abuse |
The most dangerous combinations involve MAOIs plus any serotonergic drug. MAOI + meperidine and MAOI + SSRI are classic and frequently fatal combinations.
Tintinalli's Emergency Medicine, p. 1244
Clinical Features
The syndrome exists along a spectrum from mild to fatal. Onset is typically within 2-24 hours of adding or increasing a serotonergic agent. About 90% of cases occur at therapeutic doses (drug interactions); only ~10% follow overdose.
The Classic Triad
| Domain | Major Features | Minor Features |
|---|---|---|
| Cognitive | Altered consciousness, agitation | Insomnia, restlessness, anxiety |
| Autonomic | Hyperthermia, diaphoresis | Tachycardia, hypertension/hypotension, tachypnea, mydriasis |
| Neuromuscular | Muscle rigidity, hyperreflexia, myoclonus, tremor | Akathisia, incoordination |
Key Physical Finding: Clonus
- Clonus (spontaneous or inducible) - especially at the ankles - is the hallmark neuromuscular sign
- More pronounced in the lower extremities than the upper
- Ocular clonus (rhythmic oscillations of the eyes) is highly characteristic
Severity Spectrum
- Mild: tremor, akathisia, diaphoresis, mydriasis, intermittent tremor
- Moderate: hyperthermia (38-40°C), hyperreflexia, inducible clonus, agitation
- Severe: temperature >41°C, spontaneous clonus, rigidity, seizures, rhabdomyolysis, respiratory failure, cardiovascular collapse
ROSEN's Emergency Medicine, p. 2925; Tintinalli's, p. 1244
Diagnosis
There is no gold standard laboratory test - the diagnosis is clinical based on history and examination. Labs serve to detect complications (rhabdomyolysis, hyperkalemia, renal failure).
Hunter Criteria (most sensitive - preferred)
In the setting of exposure to a known serotonergic agent, serotonin syndrome is diagnosed if any one of the following is present:
- Spontaneous clonus
- Inducible clonus + agitation or diaphoresis
- Ocular clonus + agitation or diaphoresis
- Tremor + hyperreflexia
- Hypertonia + temperature >38°C + ocular or inducible clonus
The Hunter criteria are more sensitive and have fewer false positives than the older Sternbach criteria.
ROSEN's Emergency Medicine, p. 2925
Differential Diagnosis
The most important differential is Neuroleptic Malignant Syndrome (NMS):
| Feature | Serotonin Syndrome | NMS | Anticholinergic Toxicity |
|---|---|---|---|
| Precipitant | Add serotonergic agent | Add dopamine antagonist / withdraw agonist | Add anticholinergic agent |
| Onset | Hours (usually <24h) | Days to weeks | 1-2 hours |
| Reflexes | Hyperreflexia, clonus | Bradyreflexia, lead-pipe rigidity | Normal |
| Muscle tone | Rigidity + myoclonus | Lead-pipe rigidity | Normal |
| Skin | Diaphoretic | Diaphoretic | Dry, flushed |
| GI motility | Increased (diarrhea) | Decreased | Absent bowel sounds |
The single most distinguishing sign: clonus and hyperreflexia point to serotonin syndrome, while bradykinesia and lead-pipe rigidity without clonus point to NMS.
Other differentials: malignant hyperthermia, sympathomimetic toxicity, thyroid storm, meningitis, intracranial hemorrhage, hypoglycemia.
Tintinalli's, p. 1244
Management
Step 1 - Remove the offending agent
Discontinue all serotonergic drugs immediately.
Step 2 - Benzodiazepines (cornerstone of treatment)
- Mild cases: low-dose IV diazepam 5-10 mg for agitation and rigidity
- Moderate-severe cases: large doses - IV diazepam 10-20 mg, titrated in 10 mg aliquots, or equivalent benzodiazepine
- Benzodiazepines reduce muscular hyperactivity and prevent hyperthermia-related complications
Step 3 - Temperature control
- Hyperthermia is a major driver of morbidity and mortality
- Aggressive external cooling
- Temperatures >41.1°C may require neuromuscular paralysis (non-depolarizing agent), intubation, and ICU admission
- Avoid antipyretics - fever is from muscular activity, not hypothalamic resetting
Step 4 - Cyproheptadine (adjunct)
- A 5-HT2A antagonist (antihistamine)
- Used for moderate-severe or refractory cases
- Dose: 12 mg orally (single dose; some protocols give 4-8 mg q2h, max 32 mg/day)
- No RCTs demonstrate superiority over supportive care + benzodiazepines alone
- Recent systematic review (King & Rotella, 2025) evaluated cyproheptadine in deliberate self-poisoning but evidence remains limited
- Caution: if anticholinergic toxicity remains on the differential, avoid cyproheptadine (it has anticholinergic properties)
Step 5 - Specific antidote considerations
- Chlorpromazine (5-HT2 antagonist) - sometimes used in severe cases; caution due to hypotension and seizure threshold lowering
- Avoid physostigmine (can worsen serotonergic activity)
- Avoid succinylcholine for intubation if rhabdomyolysis is present (hyperkalemia risk)
ROSEN's Emergency Medicine, p. 2925
Disposition
| Severity | Disposition |
|---|---|
| Mild (resolves quickly with discontinuation) | Observation, may discharge |
| Moderate | Monitored hospital admission |
| Severe (autonomic instability, hyperthermia, rigidity, AMS) | ICU admission |
With proper treatment, symptoms typically resolve within 24 hours. In severe cases or after long-acting serotonergic drugs (e.g., fluoxetine), symptoms may persist several days.
Key Prevention Points
- Check for drug interactions before prescribing any serotonergic combination
- Particularly hazardous combinations: MAOI + any serotonergic drug, SSRI + tramadol, SSRI + linezolid, SSRI + fentanyl (moderate risk), triptans + SSRIs
- A washout period of 2 weeks (5 weeks for fluoxetine) is required before starting an MAOI after stopping an SSRI
Sources: ROSEN's Emergency Medicine Concepts and Clinical Practice; Tintinalli's Emergency Medicine: A Comprehensive Study Guide; Adams and Victor's Principles of Neurology, 12th Ed.; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Washington Manual of Medical Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.